Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Wei He, Ph.D.
Zhejiang DTRM Biopharma
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic
Phoenix, Arizona, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Duke University Medical Center
Durham, North Carolina, United States
- University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2016
- Primary completion
- 23 Nov 2020
- Completion
- 23 Nov 2020
- Last update posted
- 27 Nov 2020
- Registered enrollment
- 48
- Registry id
- NCT02900716
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.